Melanoma Therapeutics Market Report
The report on the Global Melanoma Therapeutics Market is segmented by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs), and Region.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global melanoma therapeutics market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The report on the Global Melanoma Therapeutics Market is segmented by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs), and Region....
The Global Melanoma Therapeutics Market is expected to grow from USD 4.8 billion in 2020 to USD 9.1 billion by 2026 at a CAGR of over 11.3% during the forecast period.
Figure: Global Melanoma Therapeutics Market Size, 2020-2026 (USD Billion)
Wish to get a free sample report? Click here.
Skin cancer generally is of three types– squamous cell carcinoma, basal cell carcinoma, and melanoma. Melanoma is a type of skin cancer that forms from pigment-containing cells in the skin. It is more common in locations with a sunny climate and is the most serious of all types of skin cancers. UV radiations are the prime cause of melanoma.
As per WHO, around 132,000 cases of skin cancer occur almost every year. Further, around a 10% decrease in ozone levels is expected to lead to a rise of 4,500 skin cancer cases across the globe, which drives the product demand.
Key players operating in the global melanoma therapeutics market are-
The growing incidence of melanoma skin cancers is one of the key factors driving product consumption.
Also, growing awareness, the high adoption rate of these therapeutics among patients, technological developments further boost the market expansion. Moreover, favourable government initiatives for curbing skin cancers result in increasing healthcare expenditure, thus offering ample opportunities to the industry players. However, economic crisis, lack of product awareness in developing countries, and regulatory issues hinder the global melanoma therapeutics market growth.
Based on therapy, the global melanoma therapeutics market has been categorized into chemotherapy, immunotherapy, targeted therapy, and radiation therapy.
By region, the North America market witnessed the highest market share in 2020 and is projected to register a robust CAGR during the review period.
The COVID-19 pandemic has negatively affected the global melanoma therapeutics market in 2020. As the whole healthcare industry and medical professionals are swamped in treating the COVID-19 affected patients and in the phase of vaccine production, the cancer treatment was overlooked with postponing and delaying of cancer treatments. In India, as for surgeries, only 20% of them were performed, compared with those performed in the corresponding period in 2019.
Wish to get your customised report? Click here.
Here is the list of the group of customers that the Melanoma Therapeutics market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The melanoma therapeutics market size is expected to reach USD 9.1 billion in the foreseeable future.
The melanoma therapeutics market is expected to witness an impressive growth of 11.3% CAGR in the foreseeable future.
AstraZeneca (UK), Amgen, Inc. (The U.S), F. Hoffman-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (The U.S), Novartis AG (Switzerland), Merck & Co., Inc. (The U.S), Daiichi Sankyo Company Limited (Japan) and AB Sciences (France) are among the key players in the melanoma therapeutics market.
North America witnessed the highest share in melanoma therapeutics market in 2020.
Growing incidence of melanoma skin cancers, the high adoption rate of these therapeutics among patients, technological developments are the factors driving the growth of melanoma therapeutics market.
Melanoma therapeutics companies, Melanoma therapeutics vendors, Cancer companies, Skin care organizations, R&D companies are the target audience in the melanoma therapeutics market.